Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
IMImmunocore Holdings plc logo

Immunocore Holdings plc (IMCR)

NASDAQ Global Select · Currency in USD
$30.98 ▼ -1.14 (-3.55%)
At close: Oct 23, 4:00 PM ET. Market closed.
$30.98 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$32.12
Open
$31.78
Day's Range
$30.94 – $31.80
52 Week Range
$27.50 – $40.72
Volume
177,888
Avg. Volume
511,946
Market Cap
$1.60B
Beta (5Y Monthly)
0.82
PE Ratio (TTM)
--
EPS (TTM)
-$0.18
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$39.00

Profile: Immunocore Holdings plc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
524
CEO
Bahija Jallal

Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.17 · Revenue est. $152.86M
DateEst.Actual
Aug 6, 2026-$0.01-$0.02Miss
May 6, 2026-$0.26$0.25Beat
Feb 25, 2026-$0.28-$0.60Miss
Nov 6, 2025-$0.30$0.02Beat
Aug 7, 2025-$0.21-$0.20Beat
May 7, 2025-$0.35$0.10Beat

Analyst view

Consensus price target
$39.00 ▲ +25.9%
Range $35.00 – $43.00
Rating: Buy
Buy 64% · Hold 36% · Sell -0%

Get free alerts on IMCR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.